Business Wire

Pradaxa® (dabigatran etexilate) dual therapy showed lower rates of major bleeding versus triple therapy with warfarin in atrial fibrillation patients undergoing stent placement

Del

The RE-DUAL PCI™ trial explored anticoagulation with Pradaxa® (dabigatran etexilate) dual therapy without aspirin in non-valvular atrial fibrillation (AF) patients following percutaneous coronary intervention (PCI) and stent placement: results showed significantly lower rates of major or clinically relevant non-major bleeding events for dual therapy with Pradaxa® when compared to triple therapy with warfarin.1,2 The risk for the primary safety endpoint was 48% lower for Pradaxa® 110 mg dual therapy and 28% lower for Pradaxa® 150 mg dual therapy (relative difference), with similar rates of overall thromboembolic events. Both Pradaxa® doses have been approved by regulatory authorities around the world for stroke prevention in AF. The results were presented today as a late-breaker at the ESC Congress 20171 and have been simultaneously published in the New England Journal of Medicine. 2

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170827005045/en/

Primary endpoint 110 mg dabigatran dual therapy versus warfarin triple therapy (Graphic: Business Wi ...

Primary endpoint 110 mg dabigatran dual therapy versus warfarin triple therapy (Graphic: Business Wire)

Approximately 20–30% of patients with AF who are continuously taking an oral anticoagulant (OAC) to reduce their risk of AF-related stroke have coexisting coronary artery disease and may require a PCI using stent placement to improve blood flow to the heart.3 The combination of potent antithrombotic therapies associated with triple therapy with warfarin and two antiplatelets is associated with high rates of major bleeding in these patients.4-7 RE-DUAL PCItested an alternative treatment strategy: dual therapy with Pradaxa® and a single antiplatelet, but without aspirin.

“For physicians treating patients with atrial fibrillation who have undergone percutaneous coronary intervention with stent placement, it is paramount to balance the efficacy required with the risk of bleeding,” said Christopher Cannon, MD, cardiologist at Brigham and Women’s Hospital, lead investigator of RE-DUAL PCI™, and executive director of the Cardiometabolic Trials at the Baim Institute for Clinical Research. “Previously we did not have a lot of dedicated data on non-vitamin K oral anticoagulants in this setting; the results from RE-DUAL PCI™ are relevant to fellow physicians who care for these types of patients and are looking for an effective antithrombotic treatment regimen.”

The results were:1,2

  • Incidence of primary endpoint (time to major or clinically relevant non-major bleeding event):
    • 15.4% for Pradaxa® 110 mg dual therapy versus 26.9% for warfarin triple-therapy, which translates into a 48% lower risk
    • 20.2% for Pradaxa® 150 mg dual-therapy versus 25.7% for warfarin triple therapy, which translates into a 28% lower risk
  • Both Pradaxa® dual therapy groups also showed lower rates of major bleeding (when analysed alone, both for the ISTH* and the TIMI** major bleeding definitions) and total bleeding
  • Key secondary endpoint (combining death, myocardial infarction, stroke, systemic embolism and unplanned revascularisation):
    • Similar rates of events were observed: 13.7% for the two Pradaxa® dual therapy groups combined, versus 13.4% for warfarin triple therapy

“The results we have seen from RE-DUAL PCI™ are another great piece of evidence on the benefit Pradaxa® can offer patients with atrial fibrillation and their treating physicians; a benefit which has been shown in many situations along the treatment journey,” commented Professor Jörg Kreuzer, Vice President Medicine, Therapeutic Area Cardiovascular, Boehringer Ingelheim. “Especially if you also take into account other recent data like the RE-CIRCUIT™ study in catheter ablation, evidence from ‘real-world studies’ or the results of the RE-VERSE AD™ study in emergency situations. Together, these data paint a really compelling picture of the safety and efficacy profile of Pradaxa.”1,2, 8-18

*ISTH, International Society on Thrombosis and Haemostasis

**TIMI, Thrombolysis In Myocardial Infarction

~ Ends ~

Please click on the link for ‘Notes to Editors’ and ‘References’: https://www.boehringer-ingelheim.com/RE-DUAL-PCI-ESC-2017

For more information, please visit:  www.boehringer-ingelheim.com

Further Media Channels

www.facebook.com/boehringeringelheim

www.twitter.com/Boehringer

Contact information

Boehringer Ingelheim GmbH
Corporate Communications
Media + PR
Friederike Middeke
Phone: +49 6132 – 77 141575
Fax: +49 6132 – 77 6601
E-mail:  press@boehringer-ingelheim.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

CHTF 2017 Gathers Enterprises From 27 “One Belt, One Road” Countries22.11.2017 07:00Pressemelding

Echoing the “One Belt, One Road” initiative, the 19th China Hi-Tech Fair (CHTF 2017) which concluded on November 21, invited over 30 countries and international organizations, including Argentina, Belgium, The Czech Republic, Germany, Greece, Iran, Lithuania, Pakistan, Poland, Russia, Sweden, UK and EU, to exhibit jointly at the “One Belt, One Road” Pavilion, setting a new record in its history. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171121005458/en/ The Bavarian delegation sent 11 enterprises including leading hi-tech players such as Pfaff-Silberblau, a pioneer in mechanical drive and hoisting parts and solutions under Columbus McKinnon Engineered Products, as well as four newcomers including the most innovative startup NavVis. The Korean delegation once again broke its record in terms of the number

ION Investment Group Recapitalizes Dealogic, a Carlyle Portfolio Company22.11.2017 06:59Pressemelding

ION Investment Group ("ION") and The Carlyle Group announced a recapitalization of Dealogic, a global provider of data and analytics for the capital markets, in which ION is acquiring a controlling stake in the company and Carlyle and management are retaining significant ownership. The transaction is subject to customary approvals and is expected to close in the fourth quarter of 2017. Headquartered in New York and London with offices in Hong Kong, Budapest, Tokyo, Mumbai, Sydney, Beijing, Singapore, and São Paulo, Dealogic provides solutions to more than 800 clients globally including each of the world’s top 50 investment banks. Cam Dyer, Managing Director and Co-head of Carlyle’s global Technology, Media and Telecom group, said, “Our partnership with Tom, his team and our co-investors, including FiveW Capital, Euromoney and the company’s other co-founders, has further esta

First Tom Ford Beauty Store Opens in London21.11.2017 20:01Pressemelding

Debuting on November 20, 2017, the first TOM FORD beauty standalone store is the ultimate in luxury beauté, expressed through Tom Ford’s singular vision. Located in historic Covent Garden (3 The Market Building) this store is a pivotal moment in the evolution of the brand. The new design of light and layered grey glass sculpture creates a visually arresting play on objects and space while highlighting his collection of makeup, skincare and fragrance for women and men. Tom Ford’s inimitable touch reverberates in every dimension of the store, beginning with the LED screens lining the façade with the latest campaigns. Halos of light and floating white marble slabs showcase the exquisite design of his products, fully immersing you in the convergence of glamour and technology for the most luxurious retail environment. A complete vision of the breadth of the world of TOM FORD

Brazil Hospitality Group (BHG) Starts Partnership with AccorHotels21.11.2017 18:29Pressemelding

Brazil Hospitality Group (BHG) announces today the beginning of its partnership with AccorHotels, which will manage 17 of BHG’s owned hotels. AccorHotels also acquired LEBSPE Ltda from BHG, a company that manages The Capital São Paulo Itaim and Grand Plaza São Paulo Jardins hotels, in São Paulo; Soft Inn São Luis, in Maranhão; and Presidente Uberlândia Hotel, in Minas Gerais. BHG, the largest owner of hotel assets in Brazil, with more than R$ 1.2 billion in properties, will invest approximately R$ 300 million, in the next four years, in the renovation and repositioning of the 17 hotels that will progressively receive the flags of AccorHotels. BHG has also started a total renovation and repositioning of Marina Palace Leblon, in Rio de Janeiro which is not part of the Accor transaction. The renovation projects will be designed by renowned architects. BHG is excited to add to i

ThreatMetrix Winter ’18 Release Increases Speed, Accuracy and Reliability of Digital Identity Assessments21.11.2017 18:24Pressemelding

ThreatMetrix ®, The Digital Identity Company® today announced the Winter ’18 Release, which features new industry-level classifications and performance enhancements which bolster ThreatMetrix real-time solutions. Improving Performance of the Digital Identity Network ThreatMetrix has invested in significant upgrades across the Digital Identity Network®: SmartID has been re-architected to provide superior and faster cookie-less device recognition. This delivers improved global matching across the 4.5 billion unique devices on the ThreatMetrix Network. Improved responsiveness in the ThreatMetrix Decision Management Portal, supported by a new data warehouse and acceleration layer for reporting. Infrastructure investments across multiple global data centers to support resilience and peak thr

Porta Solutions Has Been Awarded as Excellence of the Year Innovation & Leadership for the Flexible Production at Le Fonti Awards 201721.11.2017 17:04Pressemelding

Maurizio Porta, Porta Solutions’CEO triumphed at the 32th edition of the IAIR Awards. The Award Ceremony, held at the at London Stock Exchange on the 20th of October 2017, crowned him the Excellence of the Year, Innovation & Leadership, for the Flexible Production. For being an Italian excellence since 1958, innovative leader in the sector of productive flexibility in the manufacturing world. In particular to be able to aim continually and strategically on innovation and customization to ensure the best performance and highest quality. “Flexible Production: produce what you sell, no stock, no stress, more cash" says Maurizio Porta. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171121005803/en/ Porta Solutions was awarded at the Le Fonti Awards (Photo: Business Wire) Today, the

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom